| Title | Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA) |
|---|---|
| Disease/Condition | Breast Cancer |
| Description | |
| Eligibility Criteria | Ages Eligible for Study: 18 Years and older Genders Eligible for Study: Both Accepts Healthy Volunteers: No Click here for eligibility requirements |
| Principal Investigator | Jesus Anampa Mesias, MD |
| Contact Name | Karen Fehn |
| Phone | (718) 405-8446 |
| Contact Email | CPDMUtrialinfo@montefiore.org |
| Protocol Number | IRB# 2016-6198 |
| Inclusion/Notes | This information was obtained from ClinicalTrials.gov. |
| Status | Enrolling |
| Adult Clinical Trial | Yes |
| Pediatric Clinical Trial | No |
| Adult, Pediatric, Both | Adult |